Longboard Pharmaceuticals

Longboard Pharmaceuticals is at the forefront of neurological drug development, pioneering novel, transformative medicines to address significant unmet needs in patients with devastating neurological conditions. Formed in January 2020 by Arena Pharmaceuticals, Inc. (subsequently acquired by Pfizer), Longboard is built upon a rich legacy of over two decades of world-class G protein-coupled receptor (GPCR) research. This deep expertise in GPCRs, which constitute 50-60% of all druggable targets in the human body, forms the bedrock of our innovative pipeline. Our primary focus is on advancing centrally-acting product candidates designed for high selectivity, aiming to maximize therapeutic impact while minimizing off-target effects.

Our lead investigational drug, bexicaserin (LP352), exemplifies our commitment to innovation. Bexicaserin is an oral, centrally acting, next-generation 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, meticulously engineered to have no detected activity at the 5-HT2B and 5-HT2A receptor subtypes. This high selectivity is crucial for its development in treating seizures associated with Developmental and Epileptic Encephalopathies (DEEs), a group of severe and heterogeneous epilepsies characterized by drug-resistant seizures and significant developmental delay. Beyond bexicaserin, Longboard is also advancing LP659, an oral, centrally acting sphingosine-1-phosphate (S1P) receptor subtypes 1 and 5 modulator, for the potential treatment of rare neuroinflammatory conditions. Through groundbreaking science and a patient-centric approach, Longboard Pharmaceuticals is dedicated to revolutionizing the treatment landscape for neurological diseases and improving the lives of those affected.